FIFTH AMENDMENT TO AMENDED AND RESTATED SUBLEASE BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC.Sublease • November 7th, 2017 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 7th, 2017 Company IndustryThis Fifth Amendment to the Amended and Restated Sublease (“Fifth Amendment”) made and entered into this 7th day of July 2017 (“Effective Date”), by and between NST CONSULTING, LLC, hereinafter referred to as “Sublandlord” and ACLARIS THERAPEUTICS, INC, hereinafter referred to as “Subtenant”.
AGREEMENT AND PLAN OF MERGERMerger Agreement • November 7th, 2017 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 7th, 2017 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of August 3, 2017, by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Buyer”), Aclaris Life Sciences, Inc., a Delaware corporation and a wholly owned subsidiary of the Buyer (“Merger Sub”), Confluence Life Sciences, Inc., a Delaware corporation (the “Company”), and, solely in such Person’s capacity as the representative of the Company Equityholders, Fortis Advisors LLC, a Delaware limited liability company (the “Company Equityholder Representative”).